18
APR
2020

NW Bio To Discuss Projected Schedule For Data Lock, Unblinding and Top Line Data From Its Phase 3 Clinical Trial At Annual Shareholder Meeting

Posted By :
Comments : Off
BETHESDA, Md., April 18, 2020 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that its CEO, Linda Powers, will discuss the projected schedule for reaching data lock, unblinding and reporting of top line data from its 331-patient Phase 3 trial of DCVax®-L for Glioblastoma brain cancer at the Company’s 2019 Annual...
Read More
18
FEB
2020

NW Bio Announces Annual Shareholders’ Meeting for April 18, 2020

Posted By :
Comments : Off
Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the 2019 Annual Shareholder’s Meeting will be held on April 18, 2020, at 1:00 pm in Washington, DC.
Read More
12
DEC
2019

Northwest Biotherapeutics (OTCQB:NWBO) Further Expands Senior Management Team

Posted By :
Comments : Off
For Immediate Release on Thursday, December 12, 2019 Northwest Biotherapeutics (OTCQB:NWBO) Further Expands Senior Management Team Executive With Decades of Public and Private Company Experience Joins NW Bio As CFO BETHESDA, Md., December 12, 2019 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has further...
Read More
11
DEC
2019

Northwest Biotherapeutics (OTCQB; NWBO) Announces Presentation At Inaugural Glioblastoma Drug Development Summit

Posted By :
Comments : Off
For Immediate Release on Wednesday, December 11, 2019 Northwest Biotherapeutics (OTCQB; NWBO) Announces Presentation At Inaugural Glioblastoma Drug Development Summit NW Bio CTO To Highlight History Of DCVax®-L and Phase III Clinical Trial BETHESDA, Md., December 11, 2019 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that...
Read More
10
OCT
2019

NW Bio Moves Forward With SEC Settlement

Posted By :
Comments : Off
BETHESDA, MD, October 10, 2019 – Northwest Biotherapeutics (NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement with the SEC.   As previously reported, the Company has been investigated by the SEC and has cooperated with the investigation. The Company has now successfully entered into a settlement agreement with the SEC...
Read More